CClinicalTrials.gg
Not yet recruitingNCT06668272Updated Oct 31, 2024

Small Changes Clinical Weight Loss Trial

An interventional study of Small Changes program and Standard behavioral therapy for weight loss in Obesity, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to assess the effectiveness of the Small Changes program in facilitating weight loss and to assess treatment effects on body composition, blood markers of metabolic health, and blood pressure, and to assess attrition and compliance

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Small Changes
  • weight loss
03

In context

Weight Loss

1,766 studies on the registry are indexed under Weight Loss; 277 are open to participants now.

This study's planned enrollment of 52 is below the median of 73 across 1,496 interventional studies indexed under Weight Loss.

Browse Weight Loss studies →

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 880 studies on the registry; 209 are open to participants now.

Of its 170 completed or terminated interventional studies of FDA-regulated products, 140 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Body Mass Index greater than or equal to 25
  • Stable weight with less than a 5% body weight change in the past 3 months.
  • Willingness and ability to follow a written dietary plan.
  • Ambulatory and capable of attending bi-weekly in-person and phone appointments.
  • Must reside in the geographic area for the duration of the 12-week study.
  • Clearance for weight loss by their health care provider.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating.
  • Acute medical conditions such as kidney disease, liver disease, pancreatitis, or cancer.
  • A history of bariatric surgery or gastrointestinal resection.
  • Current use of anti-obesity medications or diabetes medications, such as Glucagon-like peptide-1 receptor agonists (GLP-1RAs), that induce weight loss.
  • A history of commercial weight loss program participation within the last six months.
  • A history of anorexia nervosa or other eating disorders.
  • A history of anxiety or depression.
  • Extreme dietary restrictions or allergies that limit the ability to follow the weight loss plan.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Small Changes program

    Behavioral: Small Changes program

  • Active comparator
    Standard behavioral therapy for weight loss

    Behavioral: Standard behavioral therapy for weight loss

Interventions

  • BehavioralSmall Changes program

    Participants will be asked to track their compliance with their Small Changes diet plan using a simple checklist record . Participants will be asked to follow their diet plan every day. They are encouraged to create a diet plan that is as close to their current diet as possible. Meal options include make-from-scratch recipes, quick "grab-and-go" options,and restaurant options. There may be some time involved in learning the recipes and the routine of their new diet. It also may alter their grocery spending and habits somewhat

  • BehavioralStandard behavioral therapy for weight loss

    Participants will be provided guidance on cutting and counting calories, setting goals, reading labels, and portion sizes.

06

What researchers measure

Primary outcomes

  1. Change in weight

    Time frame: Baseline,12 weeks

Secondary outcomes

  1. Change in Hemoglobin A1C levels

    Time frame: Baseline, 12 weeks

  2. Change in triglycerides levels

    Time frame: Baseline, 12 weeks

  3. Change in total cholesterol levels

    Time frame: Baseline, 12 weeks

  4. Change in HDL cholesterol levels

    Time frame: Baseline, 12 weeks

  5. Change in fasting blood glucose levels

    Time frame: Baseline, 12 weeks

  6. Change in lean body mass

    Time frame: baseline, week 4, week 8, week 12

  7. Change in fat mass

    Time frame: baseline, week 4, week 8, week 12

  8. Compliance as measured by the percentage of meals that follow the diet plan as reported in a daily food log

    Time frame: From baseline to week 12

  9. Attrition as assessed by number of participants that complete the study

    Time frame: week 12

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06668272
Lead sponsor
The University of Texas Health Science Center, Houston
Responsible party
Leah Whigham (Associate Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Oct 31, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Nov 1, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Oct 31, 2024

Study contacts

Leah Whigham, PhD
Contact
Leah.D.Whigham@uth.tmc.edu
(915) 975-8517
Juan Aguilera
Contact
Juan.Aguilera@uth.tmc.edu
(915) 975-8520
Leah Whigham, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion